Karen N. Barnett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Karen N. Barnett has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Blair Hamilton Smith
Chronic Pain Research Group, Division of Population Health & Genomics, School of Medicine, University of Dundee, Dundee, UK
1 shared publication - Bruce Guthrie
Advanced Care Research Centre, Usher Institute, University of Edinburgh, Edinburgh, UK
1 shared publication Bukola G Adekanmi
University of Dundee
1 shared publication- Callum George Fraser
Population Health and Genomics , Ninewells Hospital and Medical School, University of Dundee , Dundee , UK
1 shared publication Charis A Marwick
University of Dundee
1 shared publication- Christine Campbell
Usher Institute, University of Edinburgh, Edinburgh, UK
1 shared publication
Latest Publications
- Open Access
System-specific multimorbidity derived from prescribing data predicts colorectal cancer outcomes: a Scottish data-linkage study
Multimorbidity, the co-existence of two or more long-term conditions, is up to three times more prevalent among people with cancer than in the general population and is associated with poorer survival, particularly for cancers with a more favourable prognosis such as colorectal cancer. In Scotland, multimorbidity is the norm among older adults, emerges earlier in socioeconomically deprived populations, and may contribute to comparatively low cancer survival rates. Despite this, the influence of multimorbidity on the colorectal cancer pathway remains poorly understood. We conducted a Scottish data-linkage study of adults diagnosed with colorectal cancer between 2010 and 2014, linking the Scottish Cancer Registry to national prescribing, hospital admissions, death registration, and bowel screening datasets. Prescribing data were used to derive overall and system-specific comorbidity measures as a proxy for multimorbidity and active disease burden. Associations with stage at diagnosis, treatment, survival, and screening uptake were examined using logistic regression and Cox proportional hazards models adjusted for demographic and clinical covariates. Among 19,043 patients, 87% had at least one prescribing-based comorbidity, most commonly cardiovascular, nervous system, and gastrointestinal conditions. Overall comorbidity burden was not associated with stage at diagnosis, although laxative-related prescribing was associated with later-stage disease. Increasing comorbidity burden reduced the likelihood of receiving any treatment and surgery, while associations varied across system-specific comorbidities. Higher comorbidity burden was also associated with increased all-cause and colorectal cancer-specific mortality, particularly among patients with respiratory, nervous system, and haematological/nutritional conditions. Screening uptake was not associated with overall comorbidity burden but did differ by system-specific comorbidity. Prescribing-based multimorbidity was highly prevalent and strongly associated with treatment patterns and mortality among patients with colorectal cancer. System-specific multimorbidity measures provided greater discrimination than overall morbidity counts, highlighting the importance of considering distinct multimorbidity profiles when assessing cancer pathways and designing targeted interventions for optimising treatment and survival.
Open AccessSystem-specific multimorbidity derived from prescribing data predicts colorectal cancer outcomes: a Scottish data-linkage study
Multimorbidity, the co-existence of two or more long-term conditions, is up to three times more prevalent among people with cancer than in the general population and is associated with poorer survival, particularly for cancers with a more favourable prognosis such as colorectal cancer. In Scotland, multimorbidity is the norm among older adults, emerges earlier in socioeconomically deprived populations, and may contribute to comparatively low cancer survival rates. Despite this, the influence of multimorbidity on the colorectal cancer pathway remains poorly understood. We conducted a Scottish data-linkage study of adults diagnosed with colorectal cancer between 2010 and 2014, linking the Scottish Cancer Registry to national prescribing, hospital admissions, death registration, and bowel screening datasets. Prescribing data were used to derive overall and system-specific comorbidity measures as a proxy for multimorbidity and active disease burden. Associations with stage at diagnosis, treatment, survival, and screening uptake were examined using logistic regression and Cox proportional hazards models adjusted for demographic and clinical covariates. Among 19,043 patients, 87% had at least one prescribing-based comorbidity, most commonly cardiovascular, nervous system, and gastrointestinal conditions. Overall comorbidity burden was not associated with stage at diagnosis, although laxative-related prescribing was associated with later-stage disease. Increasing comorbidity burden reduced the likelihood of receiving any treatment and surgery, while associations varied across system-specific comorbidities. Higher comorbidity burden was also associated with increased all-cause and colorectal cancer-specific mortality, particularly among patients with respiratory, nervous system, and haematological/nutritional conditions. Screening uptake was not associated with overall comorbidity burden but did differ by system-specific comorbidity. Prescribing-based multimorbidity was highly prevalent and strongly associated with treatment patterns and mortality among patients with colorectal cancer. System-specific multimorbidity measures provided greater discrimination than overall morbidity counts, highlighting the importance of considering distinct multimorbidity profiles when assessing cancer pathways and designing targeted interventions for optimising treatment and survival.
- Open Access
Association between antidepressants and antimicrobial resistance: a scoping review
Background: Antimicrobial resistance and depression are leading causes of global morbidity and mortality. Depression is the most common mental health disorder, with antidepressant use doubling between 2000 and 2022. Infectious diseases are increasingly difficult to treat due to some antimicrobial agents becoming ineffective. Antibiotic use is known to drive resistance in clinical bacterial infections, and laboratory studies have found that antidepressants have antibiotic properties, affecting the microbiota and stimulating mechanisms that help certain bacteria resist antibiotics. Aim: To map and evaluate existing literature on the association between antidepressants and antimicrobial resistance. Methods: This scoping review followed the modified Arksey and O’Malley’s framework. Systematic searches of MEDLINE, PubMed, Scopus and grey literature were conducted. Studies were screened for eligibility, assessed for risk of bias using ToxRTool, and analysed using a narrative synthesis. Results: Ten articles met the inclusion criteria, eight laboratory studies and two reviews. Studies reported that exposure of bacteria to antidepressants increased antibiotic resistance. There were no eligible human or animal microbiome, or population studies. Conclusion: This scoping review highlights the need for microbiome, clinical, and population studies. Associations between antidepressants and antibiotic resistance in clinical infections have implications for real-world practice, impacting clinical guidelines and patient care. Key Messages: What is already known on this topic: Depression and antibiotic resistance are both critical global health concerns. The use of antidepressant drugs is increasing and there is a growing body of laboratory evidence demonstrating that antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), exhibit antimicrobial activity against bacteria. What this study adds: This scoping review maps and synthesizes existing evidence on associations between antidepressants and antimicrobial resistance, including mechanisms involved, and identifies important gaps in the literature. The eight primary research studies included were all laboratory-based, bacterial studies. All found that exposure of bacteria to antidepressant drugs increased antibiotic resistance. There were no eligible human or animal microbiome studies, or human clinical or population studies. How this study might affect research, practice or policy: This scoping review highlights the need for more microbiome, clinical, and population studies. Associations between antidepressants and antibiotic resistance in clinical infections could have implications for real-world practice, impacting clinical guidelines and patient care.
Open AccessAssociation between antidepressants and antimicrobial resistance: a scoping review
Background: Antimicrobial resistance and depression are leading causes of global morbidity and mortality. Depression is the most common mental health disorder, with antidepressant use doubling between 2000 and 2022. Infectious diseases are increasingly difficult to treat due to some antimicrobial agents becoming ineffective. Antibiotic use is known to drive resistance in clinical bacterial infections, and laboratory studies have found that antidepressants have antibiotic properties, affecting the microbiota and stimulating mechanisms that help certain bacteria resist antibiotics. Aim: To map and evaluate existing literature on the association between antidepressants and antimicrobial resistance. Methods: This scoping review followed the modified Arksey and O’Malley’s framework. Systematic searches of MEDLINE, PubMed, Scopus and grey literature were conducted. Studies were screened for eligibility, assessed for risk of bias using ToxRTool, and analysed using a narrative synthesis. Results: Ten articles met the inclusion criteria, eight laboratory studies and two reviews. Studies reported that exposure of bacteria to antidepressants increased antibiotic resistance. There were no eligible human or animal microbiome, or population studies. Conclusion: This scoping review highlights the need for microbiome, clinical, and population studies. Associations between antidepressants and antibiotic resistance in clinical infections have implications for real-world practice, impacting clinical guidelines and patient care. Key Messages: What is already known on this topic: Depression and antibiotic resistance are both critical global health concerns. The use of antidepressant drugs is increasing and there is a growing body of laboratory evidence demonstrating that antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), exhibit antimicrobial activity against bacteria. What this study adds: This scoping review maps and synthesizes existing evidence on associations between antidepressants and antimicrobial resistance, including mechanisms involved, and identifies important gaps in the literature. The eight primary research studies included were all laboratory-based, bacterial studies. All found that exposure of bacteria to antidepressant drugs increased antibiotic resistance. There were no eligible human or animal microbiome studies, or human clinical or population studies. How this study might affect research, practice or policy: This scoping review highlights the need for more microbiome, clinical, and population studies. Associations between antidepressants and antibiotic resistance in clinical infections could have implications for real-world practice, impacting clinical guidelines and patient care.
- Open Access
- 20 March 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 134 (6) , 1717-1745
Multimorbidity and analgesic-related harms: a systematic review
- 20 March 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 134 (6) , 1717-1745
Open AccessMultimorbidity and analgesic-related harms: a systematic review
- Open Access
- 22 October 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 134 (2) , 461-491
Impact of adverse childhood experiences on analgesia-related outcomes: a systematic review
- 22 October 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 134 (2) , 461-491
Open AccessImpact of adverse childhood experiences on analgesia-related outcomes: a systematic review
- Open Access
- 12 November 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (11) , 2093
Faecal Haemoglobin Estimated by Faecal Immunochemical Tests—An Indicator of Systemic Inflammation with Real Clinical Potential
Multimorbidity is the major cause of ill-health and premature death in developed countries. The ability to identify individuals at risk of developing chronic disease, particularly multimorbidity, reliably, and simply, and to identify undiagnosed disorders, is vital to reducing the global burden of disease. This narrative review, the first of recent studies, demonstrates that raised faecal haemoglobin concentration (f-Hb) is associated with increased all-cause and cause-specific mortality and with longer-term conditions including diabetes, hypertension, cardiovascular disease, and psoriasis, and with probable intake of particulate matter. We and others have hypothesized that elevated f-Hb (measured using a faecal immunochemical test) has considerable potential to identify individuals at risk of, or who already have, early stage, undiagnosed chronic disease. If f-Hb does prove to be an effective biomarker for chronic disease and multimorbidity, individuals with detectable f-Hb, but without an obvious source of gastrointestinal blood loss, could benefit from further assessment and early intervention. To test this hypothesis rigorously, longitudinal data-linkage methodology is required linking colorectal cancer screening data, and data on patients presenting with lower gastrointestinal symptoms, with routinely collected health information.
- 12 November 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (11) , 2093
Open AccessFaecal Haemoglobin Estimated by Faecal Immunochemical Tests—An Indicator of Systemic Inflammation with Real Clinical Potential
Multimorbidity is the major cause of ill-health and premature death in developed countries. The ability to identify individuals at risk of developing chronic disease, particularly multimorbidity, reliably, and simply, and to identify undiagnosed disorders, is vital to reducing the global burden of disease. This narrative review, the first of recent studies, demonstrates that raised faecal haemoglobin concentration (f-Hb) is associated with increased all-cause and cause-specific mortality and with longer-term conditions including diabetes, hypertension, cardiovascular disease, and psoriasis, and with probable intake of particulate matter. We and others have hypothesized that elevated f-Hb (measured using a faecal immunochemical test) has considerable potential to identify individuals at risk of, or who already have, early stage, undiagnosed chronic disease. If f-Hb does prove to be an effective biomarker for chronic disease and multimorbidity, individuals with detectable f-Hb, but without an obvious source of gastrointestinal blood loss, could benefit from further assessment and early intervention. To test this hypothesis rigorously, longitudinal data-linkage methodology is required linking colorectal cancer screening data, and data on patients presenting with lower gastrointestinal symptoms, with routinely collected health information.